Get the Stockscreener App
3.32
6.43%
0.21
After Hours:
3.34
0.02
+0.60%
Agenus Inc stock is traded at $3.32, with a volume of 666.53K.
It is up +6.43% in the last 24 hours and down -15.13% over the past month.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
See More
Previous Close:
$3.11
Open:
$3.14
24h Volume:
666.53K
Relative Volume:
0.85
Market Cap:
$138.88M
Revenue:
$123.87M
Net Income/Loss:
$62.49M
P/E Ratio:
1.9886
EPS:
1.6695
Net Cash Flow:
$-87.53M
1W Performance:
+7.12%
1M Performance:
-15.13%
6M Performance:
-27.25%
1Y Performance:
-13.35%
1-Day Range:
$3.14
$3.42
1-Week Range:
$3.05
$3.42
52-Week Range:
$2.71
$7.34
Agenus Inc Stock (AGEN) Company Profile
Name
Agenus Inc
Sector
Industry
Phone
781-674-4410
Address
3 FORBES ROAD, LEXINGTON, MA
Compare AGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AGEN
Agenus Inc
|
3.335 | 129.51M | 123.87M | 62.49M | -87.53M | 1.6695 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agenus Inc Stock (AGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-19-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-18-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-18-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-06-23 | Initiated | Robert W. Baird | Outperform |
| Feb-28-23 | Resumed | H.C. Wainwright | Buy |
| Sep-28-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Apr-22-19 | Initiated | B. Riley FBR | Buy |
| Oct-28-16 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-27-16 | Reiterated | Maxim Group | Buy |
| Mar-11-16 | Upgrade | Maxim Group | Hold → Buy |
| Dec-16-15 | Initiated | Jefferies | Buy |
| Oct-27-15 | Downgrade | Maxim Group | Buy → Hold |
| Jul-27-15 | Reiterated | MLV & Co | Buy |
| Jun-11-15 | Initiated | Oppenheimer | Outperform |
| Jan-12-15 | Reiterated | Maxim Group | Buy |
| Jan-09-15 | Reiterated | MLV & Co | Buy |
| Jan-09-15 | Reiterated | Maxim Group | Buy |
| Dec-19-14 | Reiterated | Maxim Group | Buy |
| May-08-14 | Reiterated | Maxim Group | Buy |
| Mar-14-14 | Reiterated | MLV & Co | Buy |
| Oct-08-13 | Reiterated | Maxim Group | Buy |
| Jan-05-12 | Initiated | William Blair | Outperform |
| Dec-01-11 | Initiated | Global Hunter Securities | Buy |
View All
Agenus Inc Stock (AGEN) Latest News
How Agenus' Pipeline Progress Unlock Its Next Growth Phase - TradingView
Agenus: Weighing The Clinical Progress Against The Company's Cash (NASDAQ:AGEN) - Seeking Alpha
BOT+BAL Demonstrates Durable Immune Benefit in Advanced Melanoma – Agenus - Oncodaily
Agenus reports melanoma trial data for checkpoint therapy By Investing.com - Investing.com South Africa
AGEN News | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 - BioSpace
AI model identifies colorectal cancer patients likely to respond - Investing.com UK
Agenus reports melanoma trial data for checkpoint therapy - Investing.com UK
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC - 01net
New melanoma drug combo sees 42% of patients alive at 2 years - Stock Titan
AGEN Stock Dips 19.4% in a Month: Time to Buy, Hold or Sell? - TradingView
AGEN Technical Analysis | Trend, Signals & Chart Patterns | AGENUS INC (NASDAQ:AGEN) - ChartMill
Agenus (AGEN) chief takes 4,540 common shares as salary - Stock Titan
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer - BioSpace
Agenus (AGEN) price target decreased by 32.61% to 15.81 - MSN
Are options traders betting on a big move in Agenus stock? - MSN
Agenus Inc.Common Stock (NQ: AGEN - FinancialContent
Agenus (AGEN) Reports Phase 1b Results for Innovative Cancer Tre - GuruFocus
Agenus reports phase 1b liver cancer trial results - Investing.com UK
Agenus announces publication of Phase 1b BOT+BAL data - TipRanks
Agenus reports phase 1b liver cancer trial results By Investing.com - Investing.com Nigeria
Agenus Announces Resignation of Principal Accounting Officer - TipRanks
Agenus Announces Publication of Phase 1b Botensilimab and Balstil - The National Law Review
Early drug combo yields responses in liver cancer after immunotherapy - Stock Titan
Agenus (AGEN) Principal Accounting Officer Austin Charette plans May 2026 exit - Stock Titan
Advancing Strategies to Activate and Sustain Immune Response in Harder-to-Treat CancersAgenus - Oncodaily
Agenus (AGEN) Q1 Earnings and Revenues Miss Estimates - Yahoo Finance
Agenus Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Is Agenus (AGEN) Undervalued After Q1 2026? Revenue $33.7M (miss - GuruFocus
Agenus (AGEN) Releases Q1 2026 Earnings: Revenue Growth but EPS Miss - Quiver Quantitative
MSN Money - MSN
Agenus: Q1 Earnings Snapshot - WKYC
AGENUS INC 1Q 2026: Revenue $33.7M, EPS $1.02— 10-Q Summary - TradingView
[10-Q] AGENUS INC Quarterly Earnings Report - Stock Titan
Agenus Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Agenus (AGEN) Marks Significant Progress in Q1 2026 - GuruFocus
Agenus (AGEN) Cleared of SEC Investigation and Court Dismisses S - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins By Investing.com - Investing.com South Africa
Agenus (AGEN) Reports Significant Increase in Cash Reserves - GuruFocus
Agenus reports Q1 results, Phase 3 trial enrollment begins - Investing.com
Immuno-oncology developer Agenus' Q1 revenue rises, posts profit - TradingView
Zydus collaboration lifts Agenus (Nasdaq: AGEN) to Q1 2026 profit - Stock Titan
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development - marketscreener.com
Number of shareholders of Agenus Inc. – NASDAQ:AGEN - TradingView
Agenus Inc Stock (AGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):